Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Free Cash Flow (2016 - 2025)

Abeona Therapeutics has reported Free Cash Flow over the past 15 years, most recently at -$25.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$25.6 million for Q4 2025, down 36.03% from a year ago — trailing twelve months through Dec 2025 was -$84.3 million (down 44.2% YoY), and the annual figure for FY2025 was -$84.3 million, down 44.2%.
  • Free Cash Flow for Q4 2025 was -$25.6 million at Abeona Therapeutics, down from -$20.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ABEO hit a ceiling of -$5.8 million in Q3 2023 and a floor of -$33.5 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$13.6 million (2022), compared with a mean of -$14.7 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 1939.26% in 2021 and later surged 58.16% in 2022.
  • Abeona Therapeutics' Free Cash Flow stood at -$33.5 million in 2021, then surged by 58.16% to -$14.0 million in 2022, then soared by 33.85% to -$9.3 million in 2023, then crashed by 103.18% to -$18.8 million in 2024, then plummeted by 36.03% to -$25.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$25.6 million (Q4 2025), -$20.1 million (Q3 2025), and -$18.7 million (Q2 2025) per Business Quant data.